• Natasha Parekh, Yael Schenker, Chester B Good, Lynn Neilson, and William H Shrank.
• Center for Value-Based Pharmacy Initiatives, UPMC Insurance Services Division, Pittsburgh, PA, USA. parekhn@upmc.edu.
• J Gen Intern Med. 2019 Apr 1; 34 (4): 631-633.

AbstractPolypharmacy has been linked to adverse outcomes including increased risk of hospitalization, falls, and death and contributes to unnecessary healthcare spending. Deprescribing efforts aim to reduce medication burden while improving or maintaining patients' quality of life. While the practice of deprescribing is gaining momentum, quality measurement and provider reimbursement are barriers that must be addressed for deprescribing to achieve widespread adoption. Because many quality measures are focused on medication use and adherence, deprescribing efforts may negatively impact primary care provider and health plan quality ratings and value-based reimbursement. In addressing this conflict, there are opportunities to proactively align the priorities and incentives of patients, providers, and plans to promote deprescribing. In this report, we propose several actionable steps to address quality and reimbursement-based barriers such as facilitating the exclusion of those engaged in deprescribing efforts from quality measures and the development of deprescribing-based quality measures.

13 keywords...

hide…